Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

122.64 -0.15 (-0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale. 
Via Benzinga
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
5 Genius Safe Stocks to Buy for the 4th Quarter of 2023
These highly profitable, time-tested companies can deliver for their shareholders in any economic climate. 
Via The Motley Fool
4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
3 Cannabis Stocks That Should Be on Every Investor’s Radar This Fall
The cannabis industry is a quiet place where huge upside potential is building up. As more regions legalize, cannabis stocks can soar. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom
Cannabis stocks re seeing renewed interest and these seven look like reasonable buys as rescheduling approaches for weed. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Industry Changes As Marijuana Rescheduling Looms
As the Benzinga Cannabis Capital Conference returns to Chicago this Sept 27-28 for its 17th edition, gathering top CEOs, investors and leaders in the cannabis industry, let's scroll through the top... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target
Cantor Fitzgerald analyst Charles C. 
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year. 
Via Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job
For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products. 
Via Benzinga
FDA, Get It Done! Says Senator In Bipartisan Push To Regulate CBD Products Prior To Committee Hearing
A bipartisan group of U.S. lawmakers reintroduceda measure on Wednesdaythat aims to secure theFood and Drug ... 
Via Benzinga
Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say know, here is what happened. 
Via Benzinga
4 Unequaled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains are hiding in plain sight with the Nasdaq Composite still well below its November 2021 record-closing high. 
Via The Motley Fool
Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful'
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day 
Via Benzinga
10 Cannabis Stocks That Could Go Sky High In 2023
With cannabis legalization gaining momentum, investing in cannabis presents a lucrative opportunity. Investors may want to explore cannabis stocks to enhance their portfolios. Here are the top 10... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.